Athenex announced that target enrollment of 360 patients in the Oraxol Phase 3 clinical trial in metastatic breast cancer has been achieved on schedule. Athenex also reaffirms that top line data from the study is expected to be available in mid-2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.